New EGFR-Targeted Therapies Enter the NSCLC Landscape

Megan May, PharmD, discusses fitting newer targeted therapies into the treatment paradigm for EGFR exon 20 insertion mutation-positive non–small cell lung cancer.

Megan May, PharmD, assistant professor, University of Kentucky, discusses fitting newer targeted therapies into the treatment paradigm for EGFR exon 20 insertion mutation-positive non–small cell lung cancer (NSCLC).

Currently, mobocertinib (Exkivity), an EGFR tyrosine kinase inhibitor, is under active investigation for the treatment of EGFR exon 20 insertion-positive NSCLC. Another drug being researched that has demonstrate promise for the treatment of these patients is amivantamab-vmjw (Rybrevant).

0:08 | One thing that's unique with this medication, I mentioned, it's targeting that EGFR exon 20 insertion mutation. And currently, there are 2 different options that are approved in the setting. So, 1 is an IV antibody, and its amivantamab. And then we also have the oral agent that we're talking about the mobocertinib.

0:34 | One thing that's interesting is going to be determining how do you use these medications? Do you use them in combination with chemotherapy? Or do you keep them as monotherapy like they're approved right now? And then also, what is the order or sequencing between the 2 of these? So do you start with the amivantamab and then when you progress you go to the mobocertinib, or vice versa. So, I think that's going to be interesting to find out where we go over the next years with sequencing in this specific target mutation.